Clinical Trials
12 trialsNCT05092451 2026-05-06
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT03622788 2025-12-17
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02356159 2025-09-30
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT06119685 2025-06-03
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
Phase 1/2 Recruiting
NCT05000450 2024-06-28
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics
Phase 1/2 Terminated
NCT00048412 2020-01-18
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Baylor College of Medicine
Phase 1/2 Completed
NCT01875237 2019-07-16
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03322735 2017-12-29
Study of BCMA CAR-T in Multiple Myeloma
Henan Cancer Hospital
Phase 1/2 Unknown
NCT00579111 2016-05-04
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Baylor College of Medicine
Phase 1/2 Terminated
NCT00809276 2015-02-16
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00056966 2012-06-29
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
Baylor College of Medicine
Phase 1/2 Completed